Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study unconfirmed

Story checked

Decipher tissue-based molecular test helps personalize high-risk prostate cancer treatment (opens in a new tab)

news-medical.net · 2026-10-23

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims
3

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

The literature search

15 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 5Not checkedUCL researchers will present findings suggesting that the Decipher tissue-based molecular test may help personalize treatment for men with high-risk prostate cancer.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 5Not checkedThe team analyzed Decipher scores from two datasets: real-world data from 27,607 men, with 5,956 analyzed for outcomes, and 401 men with non-metastatic prostate cancer randomized within the STAMPEDE abiraterone trial.View evidenceHide evidence

As stated27,607 real-world cases; 5,956 analyzed for outcomes; 401 trial participants

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 5Not checkedHigher Decipher scores consistently predicted worse outcomes; for every 0.1 increase in the score, the risk of distant metastasis increased with an adjusted hazard ratio of 1.49 and the risk of death from prostate cancer had a hazard ratio of 1.38.View evidenceHide evidence

As statedaHR 1.49 for distant metastasis; HR 1.38 for prostate cancer death per 0.1 score increase

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 5Not checkedThe Decipher score predicted which patients whose cancers had not yet spread to their lymph nodes would benefit from adding abiraterone in preventing spread to distant parts of the body.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 5Not checkedThe lead researcher said the findings suggest a genomic test could help personalize treatment by identifying men with low Decipher scores who might be spared more intensive treatment and men with high scores who could be prioritized for it, but further validation is needed before routine use.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

Abiraterone May Offer Improved QOL Over Docetaxel in Locally Advanced/Metastatic Prostate Cancer

Default Digital Object Group · 2020 · Crossref

Source (opens in a new tab)
Candidate

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.

Research Square · 2023 · PubMed

Tessa (opens in a new tab)Source (opens in a new tab)

Explore all search results